Theravance Biopharma, Inc.
TBPH
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (Jā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$18.79
Price+3.36%
$0.61
1Y
Price
Market Cap
$952.150m
Small
Price/Earnings 3y Avg5y Avg
33x
Premium
Premium
Financials Overview
Key metrics over the past few years-9.5%
EBITDA Margin+18.1%
Net Profit Margin-32.6%
Free Cash Flow MarginRevenue
$80.327m
+24.8%
1y CAGR+16.2%
3y CAGR+10.4%
5y CAGREarnings
$29.344m
+152.0%
1y CAGR+14.5%
3y CAGR+145.2%
5y CAGREPS
$0.57
+149.6%
1y CAGR+51.7%
3y CAGR+52.8%
5y CAGRBook Value
$232.681m
$415.460m
Assets$182.779m
Liabilities$44.595m
DebtDebt to Assets
10.7%
-1.7x
Debt to EBITDAFree Cash Flow
$243.479m
+2151.7%
1y CAGR+765.3%
3y CAGR+576.8%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company